Tag Archives: pulmonary hypertension

Introduction Pulmonary arterial hypertension (PAH) is a devastating disease characterised by irreversible pulmonary vascular proliferation and remodelling, resulting ultimately in right heart failure. Current therapy targets the nitric oxide, endothelin and prostacyclin pathways to promote pulmonary vasodilatation and reduce right ventricular afterload.1,2 Selexipag is an oral selective prostacyclin-receptor agonist that is used in the treatment of PAH. In the GRIPHON (Prostacyclin [PGI2] Receptor Agonist In Pulmonary Arterial Hypertension) trial the optimum dose of selexipag for maximum therapeutic benefit frequently differed between individ

Introduction Myxoma is the most common primary cardiac tumour, found in the left atrium in 75% of cases.1,2 Clinical features range from being asymptomatic to symptoms of mitral stenosis, embolisation and systemic illness.3-5 Pulmonary complications, including pulmonary hypertension,4,6,7 pulmonary infarction8 and lymphadenopathy,9 though uncommon, have been reported. Our patient presented with a pulmonary triad of all the complications mentioned above and all of them resolved immediately following successful excision of the tumour. We hope to report this case for educational and clinical purposes, due to the unusual combination of pulmonary

PH update from ERS The 2015 ESC/ERS guidelines for the diagnosis and treatment of PH Updated collaborative guidelines from the ERS and ESC on the diagnosis and management of pulmonary hypertension (PH) were presented at the ERS by Professor Marc Humbert (chairperson of the ERS taskforce). PH diseases continue to be classified into one of five groups and its haemodynamic definition remains unchanged, with a mean pulmonary artery pressure ≥ 25 mmHg at right heart catheterisation. Right heart catheterisation There is a high prevalence of left heart disease in the PH population. As the pulmonary arterial wedge pressure (PAWP) may be normal in

(more…)

(more…)

New drugs for diabetes A new DPP-4i for the management of type 2 diabetes, alogliptin (Vipidia®) has been launched by Takeda in the UK following data from EXAMINE, an outcome trial conducted in high risk acute coronary syndrome patients (see Br J Cardiol 2013;4:131) where the drug significantly reduced glucose levels and also demonstrated cardiovascular safety. Alogliptin and the fixed-dose combination product alogliptin and metformin (Vipdomet®) are now available in the UK. Alogliptin is licensed for the treatment of type 2 diabetes mellitus in adults aged 18 years and older to improve glycaemic control in combination with other glucose-lo

No content available